Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BALTIMORE, Sept. 29 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) today announced that its stockholders approved the merger transaction pursuant to which Guilford will...
MGI PHARMA, INC. (Nasdaq:MOGN), an oncology and acute care focused biopharmaceutical company, and Guilford Pharmaceuticals Inc. (Nasdaq:GLFD), a biopharmaceutical company engaged in the research...
BALTIMORE, Aug. 8 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) today reported financial results for the quarter ended June 30, 2005. For the second quarter, Guilford...
BALTIMORE, Aug. 2 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) will host a conference call and live audio webcast to announce its second quarter 2005 financial results...
BALTIMORE, Aug. 2 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) will host a conference call and live audio webcast to announce its second quarter 2005 financial results...
Guilford Pharmaceuticals Implements Strategic Reorganization to Align Resources With Corporate Strategy BALTIMORE, May 24 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD...
Guilford Pharmaceuticals Presents New NAALADase Inhibitor Data in Chemotherapy-Induced Neuropathy at ASCO BALTIMORE, May 18 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD...
Guilford Pharmaceuticals Announces Promising Results at ASCO in Study of Newly Diagnosed High Grade Malignant Glioma Study Suggests Safety of GLIADEL(R) Wafer and Temozolomide Used in Combination...
AGGRASTAT(R) Injection Strategy Trial Data Published in JAMA BALTIMORE, May 11 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) today announced the publication of results...
Guilford Pharmaceuticals Reports 2005 First Quarter Results BALTIMORE, May 9 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) today reported financial results for the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
